According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of non-Hodgkin lymphoma: diffuse large B- cell lymphoma and follicular lymphoma.
In MMX, investigatores Weissman Cornelius ducitur, MD, medicinae director de Stanford stem cell Biology et Regenerative Institutum ostendit quod fere omnis cancer cellulis sunt operuit cum a dapibus vocavit CD2010, quod potest ludere a "nolite manducare me" BELLICUM macrophages est.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
XXII De aegris participatione in iudicio, quam signanter reducitur orci cancer aegris XI et eliminated VIII aegris erant omnia signa, et cancer. Et alii tres ad aegris Respondeo dicendum quod iudicium non est mortuus debitum ad morbo progressio et curatio. Inquisitores participantium de longinquo iam prospexerat, cum tantum minor parte effectus.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new immunotherapy is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
